BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Organovo Joins With Oregon Health & Science University (OHSU) to Bio-Engineer Cancer Tissue for Drug R&D


1/30/2013 8:08:22 AM

Along the way to developing technology for bio-engineering human livers, kidneys, and other vital organs, Organovo CEO Keith Murphy says the San Diego startup realized its 3-D bio-printing technology could be used to address a huge unmet need more immediately. As Murphy explained 18 months ago, Big Pharma companies have been searching for better and more accurate ways to test their experimental drug compounds in the laboratory. But there are limits to predicting clinical outcomes from tests that use lab animals or cancer cell lines. So Organovo, with bio-printer technology that lays down a pattern of cultured cells, began to supply customers like Pfizer (NYSE: PFE) with 3-D samples of cells that look and act more like real human tissue. Now the six-year-old startup is taking this line of business in a new direction. Organovo is today announcing a partnership with the Knight Cancer Institute at the Oregon Health & Science University (OHSU) in Portland, OR, to make 3-D human tissue samples even more accurate in terms of assessing drug candidates during pre-clinical development. A statement from the partners quotes Joe W. Gray, director of OHSU’s Center for Spatial Systems Biomedicine, saying, “Using Organovo’s bioprinting technologies, we plan to create new models to understand cancer disease mechanisms and metastatic progression, which can be used to discover and test new targeted therapies.” Organovo’s bio-printer operates much like an inkjet printer. The company showed in late 2010 it could grow bio-engineered blood vessels by “printing” cultured human cells in rings, layer upon layer, supported by a jello-like hydrogel so the cells could fuse into a 3-D, tunnel-like structure. Now Oranovo and OHSU plan to use the same technology to create 3-D tissue samples so each cell can interact with adjoining cells, so they react to drug compounds much as they would in the body.

Read at Xconomy
Read at Seeking Alpha

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->